
ImpediMed Investor Relations Material
Latest events

Q3 2025
ImpediMed
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImpediMed Limited
Access all reports
ImpediMed Limited is an Australian medical technology company specializing in bioimpedance spectroscopy (BIS) technology for non-invasive health assessments. The company’s primary products focus on the early detection, monitoring, and management of lymphedema, as well as body composition and fluid status assessments. ImpediMed’s technology is used in healthcare settings to support patient care in oncology, renal health, and other medical fields where fluid management is critical. ImpediMed Limited is headquartered in Brisbane, Australia, and its shares are listed on the ASX.
Key slides for ImpediMed Limited


Q2 2025
ImpediMed Limited


Q3 2025
ImpediMed Limited
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
IPD
Country
🇦🇺 Australia